I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.
squamous cell carcinoma
cancer therapy
esophageal cancer
lung cancer
renal pelvis
- 0 views
- 05 Aug, 2020